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In the past HepG2 cells have been con-
sidered to show only little similarity to pri-
mary human hepatocytes (Godoy et al., 
2013; Hewitt et al., 2007). However, recently 
it has become clear that the phenotype of 
HepG2 cells strongly depends on culture 
conditions. In a recent study, Ramaiahgari et 
al. (2014) cultivated HepG2 cells in sphe-
roids. In this culture system the cells stopped 
proliferation and strongly upregulated phase 
I and phase II drug metabolizing enzymes 
and transporters (Ramaiahgari et al., 2014). 
Moreover, albumin and urea metabolizing 
enzymes were upregulated. This study shows 
that the potential of HepG2 cells may have 
been underestimated in the past. A critical 
aspect seems to be that they have to be kept 
in three dimensional culture systems. 
Much effort has been invested in the es-
tablishment of hepatocyte culture systems 
that help to identify hepatotoxic compounds 
(Ilkavets, 2013; Abdelhamid et al., 2013; 
Vinken et al., 2013; Hasmall et al., 2001; 
Waterfield et al., 1998; Mennes et al., 1994; 
Krijt et al., 1993; Godoy et al., 2009; Adler 
et al., 2014; Maruf and O’Brien, 2014). In 
recent years HepG2 cells have become more 
and more popular for this purpose (Mostafa-
vi-Pour et al., 2013; Shan et al., 2013; 
Krithika et al. 2013; Doricakova et al., 2013; 
Straser et al. 2011; Dias da Silva et al., 2013; 
Horinouchi et al., 2014; Wang et al., 2014). 
One reason for their frequent application 
may be that they are freely available in con-
trast to some other cell lines obtained from 
human liver tumors that are only commer-
cially available. Another successful applica-
tion of HepG2 cells is expression of human 
genes (Lahoz et al., 2013). The group of 
Castell and Gomez-Lechon have specialized 
in this field (Tolosa et al., 2012; Donato et 
al., 2010; 2008). Recently, five P450 en-
zymes have been expressed simultaneously 
in HepG2 cells resulting in a powerful test 
system for compounds that require metabolic 
activation (Tolosa et al., 2013). It is clear 
that primary human hepatocytes currently 
still represent the gold standard for hepato-
toxicity testing (Hengstler et al., 2000; 2009; 
Hewitt et al., 2007). Future studies will have 
to show to which degree HepG2 based cul-
ture system can be used to predict hepatotox-
ic compounds in vitro.  
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